Food and Drug Administration to begin clinical studies of a proprietary small molecule inhibitor of the CCR2 chemokine receptor
with which it expects to complete Phase I studies in 2006.
based in Bala Cynwyd, Pennsylvania, is an emerging biopharmaceutical company that is focusing on the development of diagnostic and therapeutic products related to adenosine 5'-triphosphate, or ATP, and ATP-related P2 receptors
An injection of etomidate or propofol prevented this reflex in typical mice but not in the knockin mice with the mutant GABA-A receptor
, the team reported in the Feb 17, 2003 FASEB Journal.
We next determined whether we could measure brevetoxin activity in blood extracted from the card using receptor
To address this need, Predix Pharmaceuticals has moved rapidly from biological proof of concept, which demonstrated the activation of 5-HT2B receptors
as a limiting step in the development of PH, to the initiation of Phase I trials.
Their sensing system is a silicon square, 1 cm by 1 cm, with a pattern of open, conical baskets that hold sensing beads covered with various chemical receptors
Partial interferon-gamma receptor
signaling chain deficiency in a patient with bacille Calmette-Guerin and Mycobacterium abscessus infection.
2002) have shown that BXR and SXR (also known as PXR) are functionally distinct and that BXRs do not function as xenobiotic receptors
Our first step in using a newly discovered receptor
gene for drug discovery is the identification of the natural ligand that works on the receptor
in the body," said Theresa A.
The soluble TNF receptor
is the second receptor
product to enter clinical study.
today announced a worldwide multi-target strategic alliance to discover, develop and market novel medicines targeting four chemokine and chemoattractant receptors
for the treatment of a variety of inflammatory disorders, including Traficet-EN(R) in late stage development for the treatment of inflammatory bowel disease (IBD).
By regulating how calcium moves within animal cells, that receptor
plays an essential role in processes such as muscle contraction.
The team examined whether EDCs that can bind to vertebrate estrogen receptors
and interfere with normal hormone action would also influence luteolin--NodD receptor
NASDAQ: IMNX) indicate that soluble versions of both TNF receptor
and Interleukin-1 (IL-1) receptor
turn off inflammatory responses in animal models of arthritis and septic shock.
Preclinical data will be presented on: PRX-03140, a highly selective, proprietary serotonin 4 (5-HT4) receptor
agonist being developed for Alzheimer's disease; PRX-08066, a highly selective, proprietary 5-HT2B receptor
antagonist being developed for the treatment of pulmonary hypertension (PH) and PH associated with chronic obstructive pulmonary disease; and PRX-07034, a highly selective, proprietary 5-HT6 receptor
antagonist being developed for the treatment of obesity and also for cognitive impairment (associated with Alzheimer's disease or schizophrenia).